Paul Diolosa is President & CEO at American Regent, a Daiichi Sankyo Group Company specializing in sterile injectables for healthcare providers across the United States and Canada.
In his 17 years with the company, Paul has led transformative investments in facilities, equipment, and people, including a state-of-the-art manufacturing expansion with capacity to help millions of patients. For Paul, these millions aren’t just numbers: “Every vial we produce has a name and a face attached to it.”
Early Lessons in Resilience
That sense of purpose didn’t appear overnight; it was built over a lifetime of hands-on work. Growing up in a modest household, Paul Diolosa learned the value of hard work early. “My father worked two jobs—one for the local township and another running an auto repair shop out of our home garage,” he recalls. By age 12, Paul was already working on cars, a hands-on experience that shaped his future. As the first in his family to attend college, he pursued mechanical engineering.
His hands-on skills caught attention during a college internship at Estée Lauder which led to a full-time position after graduation. There, he designed lipstick machines and managed AutoCAD drawings. “I even took ownership of a product I spent months developing,” he says, a formative experience that sparked his interest in leadership and innovation.
The Path to Leadership
Encouraged by his father and supported by Estée Lauder’s tuition reimbursement program, Paul pursued an MBA immediately after his bachelor’s degree. “I wanted to learn more about business processes and prepare for management,” he explains. Immersed in case studies and corporate histories, he honed the strategic thinking skills that would later define his leadership style.
Finding Purpose in Pharmaceuticals
Those business skills soon led to bigger opportunities. Initially drawn to the pharmaceutical industry for financial reasons, Paul quickly discovered deeper meaning.
Recruited by Altana Pharmaceuticals as head of engineering at just 26, he embraced the challenge. “Sterile injectables felt far more purposeful than creams and ointments,” he reflects.
When the opportunity at ARI (then called Luitpold) came along in 2008, it felt right. “I knew they needed my help, and I needed theirs,” he says. Seventeen years later, that decision has proven transformative.
American Regent's global footprint
Challenge Becomes Triumph
However, transformative decisions often come with hard realities. When Paul first toured ARI’s Shirley site, he was alarmed by years of underinvestment. “I made the CEO commit $100 million to address poor practices,” he recalls. Shortly after, the FDA issued a warning letter, a pivotal moment that tested his resolve.
What followed required determination and persistence. Through six changes in heads of quality, Paul remained the steady force leading efforts that lifted the warning letter and revitalized the company. Under his leadership, ARI grew from $500 million in revenue to $1.4 billion, expanded from one site to five globally including one in France, and invested $1.5 billion in capital improvements.
“The most significant change wasn’t physical, it was in mindset,” he says. “Status quo was once acceptable. Now, everyone understands that if something is worth doing, it’s worth doing right.”
Innovation and Global Impact
New Albany, Ohio, USA, filling facility groundbreaking in 2024
The foundation of quality and discipline now positions ARI for its next chapter. Today, ARI stands as a best-in-class sterile injectable manufacturer, contributing to Daiichi Sankyo’s transformation into a global oncology leader. A new state-of-the-art filling facility addition in New Albany, Ohio, will produce Daiichi Sankyo’s oncology products for the U.S. market.
Paul is equally excited about ARI’s pipeline: antipsychotics, oncology generics, and a potential first-in-class osteoarthritis therapy. “What excites me most,” he says, “is helping patients while providing stability for our employees.”
A Philosophy of Family
Through all the growth and change, Paul has worked to preserve something essential. His leadership philosophy is simple: “Treat colleagues like family around the dinner table.” He fosters collaboration and trust through town halls, site visits, and open-door sessions. “We spend more time with colleagues than with our own families, so it’s easier when we appreciate what everyone brings to the table,” he explains.
Patient-centricity drives this approach. When ARI began packaging a life-saving cancer medicine, Paul gathered the team to explain its impact. “That person could be your mother, your son, your colleague, your friend,” he says. “Keeping people aware of that purpose helps with motivation.”
Looking Ahead
The road ahead brings new pressures in market challenges, but Paul’s outlook remains steady and focused on growth and innovation. “This has been a roller coaster ride, but there’s no place I’d rather work than ARI,” he says. His greatest joy is seeing his team succeed and celebrating shared accomplishments.
Beyond Work
Outside the office, Paul enjoys restoring cars, lifting weights—a nod to his days as a competitive powerlifter—and spending time with family and friends. “A perfect weekend for me is a backyard barbecue,” he shares with a smile.
As ARI continues to evolve, Paul’s vision remains clear: “When I retire someday, what will truly make me happy is knowing the company has a bright future and continues to help as many patients as possible.” He credits the opportunities he’s been given by Daiichi Sankyo and Ken Keller, the previous CEO of ARI, for helping make that future possible. That support matters to him, but his focus always returns to the employees. “I’m happy knowing our work supports meaningful opportunities for our staff. Because none of this happens without the people who do the work.”